Abstract
The appropriate development of hemostasis encompasses a delicate equilibrium between anti- and prothrombotic forces developing during three distinct phases (primary hemostasis, coagulation and fibrinolysis) that are closely linked to each other and precisely regulated to close vessel wounds, promote vascular healing and maintain vessel patency. Imbalance in each of these systems produces either hemorrhagic or thrombotic disorders. Inherited bleeding disorders, caused by quantitative or qualitative alterations of either platelets or plasma proteins involved in blood coagulation and fibrinolysis, may lead to serious and lifelong bleeding conditions, the severity of which is inversely associated with the degree of the underlying defect. Rapid and reliable identification of these pathologies is worthy of focus to allow the adoption of appropriate substitutive or supportive antihemorrhagic therapies. Evaluation of the hemorrhage-prone patient requires careful recording of the medical history, attention to pertinent physical findings and the discretionary use of laboratory resources. Owing to the low diagnostic efficiency of clinical history and examination, an appropriate and reliable laboratory approach, encompassing first- and second-line testing, is essential to screen, diagnose and monitor patients with bleeding diatheses. As both the analytical sensitivity and responsiveness of traditional coagulation assays to different abnormalities differ widely, each laboratory should establish individual guidelines based on field experience and on reagent and instrument characteristics. Emerging evidence indicates that the implementation of global coagulation tests, such as the thrombin generation assay and clot waveform analysis, would provide additional information for clinical decision-making for patients with inherited bleeding disorders.
Clin Chem Lab Med 2007;45:2–12.
References
1. Manzato F, Lippi G, Franchini M, Guidi GC. Physiopathology of blood coagulation: recent acquisitions. Biochim Clin2004;28:1–3.Search in Google Scholar
2. Stassen JM, Arnout J, Deckmyn H. The hemostatic system. Curr Med Chem2004;11:2245–60.10.2174/0929867043364603Search in Google Scholar
3. MacFarlane RG. An enzyme cascade in the blood clotting mechanism and its function as a biochemical amplifier. Nature1964;202:498–9.10.1038/202498a0Search in Google Scholar
4. Davie EW, Ratnoff OD. Waterfall sequence for intrinsic blood clotting. Science1964;145:1310–2.10.1126/science.145.3638.1310Search in Google Scholar
5. Monroe DM, Hoffman M, Roberts HR. Platelets and thrombin generation. Arterioscler Thromb Vasc Biol2002;22:1381–9.10.1161/01.ATV.0000031340.68494.34Search in Google Scholar
6. Renne T, Nieswandt B, Gailani D. The intrinsic pathway of coagulation is essential for thrombus stability in mice. Blood Cells Mol Dis2006;36:148–51.10.1016/j.bcmd.2005.12.014Search in Google Scholar
7. Anand M, Rajagopal K, Rajagopal KR. A model for the formation and lysis of blood clots. Pathophysiol Haemost Thromb2005;34:109–20.10.1159/000089931Search in Google Scholar
8. Hoffman M. A cell-based model of coagulation and the role of factor VIIa. Blood Rev2003;17(Suppl 1):S1–5.10.1016/S0268-960X(03)90000-2Search in Google Scholar
9. Bouma BN, Meijers JC. Role of blood coagulation factor XI in downregulation of fibrinolysis. Curr Opin Hematol2000;7:266–72.10.1097/00062752-200009000-00002Search in Google Scholar PubMed
10. Lasne D, Jude B, Susen S. From normal to pathological hemostasis. Can J Anaesth2006;53:S2–11.10.1007/BF03022247Search in Google Scholar PubMed
11. Castaman G, Federici AB, Rodeghiero F, Mannucci PM. von Willebrand's disease in the year 2003: towards the complete identification of gene defects for correct diagnosis and treatment. Haematologica2003;88:94–108.Search in Google Scholar
12. Federici AB. Clinical diagnosis of von Willebrand disease. Haemophilia2004;10:169–76.10.1111/j.1365-2516.2004.00991.xSearch in Google Scholar PubMed
13. Laffan M, Brown SA, Collins PW, Cumming AM, Hill FG, Keeling D, et al. The diagnosis of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors' Organization. Haemophilia2004;10:199–217.10.1111/j.1365-2516.2004.00894.xSearch in Google Scholar
14. Federici AB, Castaman G, Mannucci PM; Italian Association of Hemophilia Centers (AICE). Guidelines for the diagnosis and management of von Willebrand disease in Italy. Haemophilia2002;8:607–21.10.1046/j.1365-2516.2002.00672.xSearch in Google Scholar
15. Hayward CP. Inherited platelet disorders. Curr Opin Hematol2003;10:362–8.10.1097/00062752-200309000-00007Search in Google Scholar
16. Balduini CL, Cattaneo M, Fabris F, Gresele P, Iolascon A, Pulcinelli FM, Savoia A; Italian Gruppo di Studio delle Piastrine. Inherited thrombocytopenias: a proposed diagnostic algorithm from the Italian Gruppo di Studio delle Piastrine. Haematologica2003;88:582–92.Search in Google Scholar
17. Mannucci PM, Tuddenham EG. The hemophilias – from royal genes to gene therapy. N Engl J Med2001;344:1773–9.10.1056/NEJM200106073442307Search in Google Scholar
18. Brettler DB. Inhibitors in congenital haemophilia. Baillieres Clin Haematol1996;9:319–29.10.1016/S0950-3536(96)80066-7Search in Google Scholar
19. Peyvandi F, Kaufman RJ, Seligsohn U, Salomon O, Bolton-Maggs PH, Spreafico M, et al. Rare bleeding disorders. Haemophilia2006;12(Suppl 3):137–42.10.1111/j.1365-2516.2006.01271.xSearch in Google Scholar PubMed
20. Cesarman-Maus G, Hajjar KA. Molecular mechanisms of fibrinolysis. Br J Haematol2005;129:307–21.10.1111/j.1365-2141.2005.05444.xSearch in Google Scholar PubMed
21. Patrushev LI. Genetic mechanisms of hereditary hemostasis disorders. Biochemistry (Mosc)2002;67:33–46.10.1023/A:1013995929506Search in Google Scholar
22. Largent V, Deneys V, Brichard B, Chantrain C, Vermylen C. Bleeding diathesis in a child with normal screening tests: think about fibrinolysis. Eur J Pediatr2005;64:587–8.10.1007/s00431-005-1683-2Search in Google Scholar PubMed
23. Dewerchin M, Collen D, Lijnen HR. Enhanced fibrinolytic potential in mice with combined homozygous deficiency of alpha2-antiplasmin and PAI-1. Thromb Haemost2001;86:640–6.10.1055/s-0037-1616099Search in Google Scholar
24. Minowa H, Takahashi Y, Tanaka T, Naganuma K, Ida S, Maki I, et al. Four cases of bleeding diathesis in children due to congenital plasminogen activator inhibitor-1 deficiency. Haemostasis1999;29:286–91.10.1159/000022514Search in Google Scholar
25. Nesheim M. Thrombin and fibrinolysis. Chest2003;124:33S–9S.10.1378/chest.124.3_suppl.33SSearch in Google Scholar
26. Aledort LM. Why thrombin generation? From bench to bedside. Pathophysiol Haemost Thromb2003;33:2–3.10.1159/000071635Search in Google Scholar
27. Wojtkowski TA, Rutledge JC, Matthews DC. The clinical impact of increased sensitivity PT and APTT coagulation assays. Am J Clin Pathol1999;112:225–32.10.1093/ajcp/112.2.225Search in Google Scholar
28. Teitel JM. Clinical approach to the patient with unexpected bleeding. Clin Lab Haematol2000;22(Suppl 1):9–11.10.1046/j.1365-2257.2000.00002.xSearch in Google Scholar
29. Blanchette VS, Sparling C, Turner C. Inherited bleeding disorders. Baillieres Clin Haematol1991;4:291–332.10.1016/S0950-3536(05)80162-3Search in Google Scholar
30. Coffin CM. Potentially catastrophic bleeding disorders. Approach to diagnosis and management. Postgrad Med1989;86:217–21.10.1080/00325481.1989.11704399Search in Google Scholar PubMed
31. Lippi G, Franchini M, Brazzarola P, Manzato F. Preoperative screening: the rationale of measuring APTT in risk assessment. Haematologica2001;86:328.Search in Google Scholar
32. Chuansumrit A, McCraw A, Preston EF. Essential issues of laboratory investigation for patients with haemophilia and bleeding disorders. Haemophilia2004;10(Suppl 4):105–8.10.1111/j.1365-2516.2004.00988.xSearch in Google Scholar PubMed
33. Burk CD, Miller L, Handler SD, Cohen AR. Preoperative history and coagulation screening in children undergoing tonsillectomy. Pediatrics1992;89:691–5.10.1542/peds.89.4.691Search in Google Scholar
34. Acosta M, Edwards R, Jaffe EI, Yee DL, Mahoney DH, Teruya J. A practical approach to pediatric patients referred with an abnormal coagulation profile. Arch Pathol Lab Med2005;129:1011–6.10.5858/2005-129-1011-APATPPSearch in Google Scholar PubMed
35. Lillicrap D, Nair SC, Srivastava A, Rodeghiero F, Pabinger I, Federici AB. Laboratory issues in bleeding disorders. Haemophilia2006;12(Suppl 3):68–75.10.1111/j.1365-2516.2006.01279.xSearch in Google Scholar
36. Palmer RL. Laboratory diagnosis of bleeding disorders. Basic screening tests. Postgrad Med1984;76:137–42.10.1080/00325481.1984.11698822Search in Google Scholar
37. Franchini M, Lippi G. Multidisciplinary approach to the diagnosis of congenital bleeding disorders. Biochim Clin2002;27:10–5.Search in Google Scholar
38. Lippi G, Montagnana M, Salvagno GL, Poli G, Franchini M, Guidi GC. Influence of warfarin therapy on activated factor VII clotting activity. Blood Coagul Fibrinolysis2006;17:221–4.10.1097/01.mbc.0000220247.97164.eaSearch in Google Scholar
39. Lowe GD, Rumley A, Mackie IJ. Plasma fibrinogen. Ann Clin Biochem2004;41:430–40.10.1258/0004563042466884Search in Google Scholar
40. Chitolie A, Mackie IJ, Grant D, Hamilton JL, Machin SM. Inaccuracy of the ‘derived’ fibrinogen measurement. Blood Coagul Fibrinolysis1994;5:955–7.10.1097/00001721-199412000-00012Search in Google Scholar
41. Givens TB, Braun PJ. Classification of factor deficiencies from coagulation assays using neural networks. Int J Med Inform1997;46:129–43.10.1016/S1386-5056(97)00065-8Search in Google Scholar
42. Barna L, Triplett DA. Use of the activated partial thromboplastin time for the diagnosis of congenital coagulation disorders: problems and possible solutions. Ric Clin Lab1989;19:345–54.10.1007/BF02871824Search in Google Scholar PubMed
43. Murray D, Pennell B, Olson J. Variability of prothrombin time and activated partial thromboplastin time in the diagnosis of increased surgical bleeding. Transfusion1999;39:56–62.10.1046/j.1537-2995.1999.39199116895.xSearch in Google Scholar PubMed
44. Brandt JT, Arkin CF, Bovill EG, Rock WA, Triplett DA. Evaluation of APTT reagent sensitivity to factor IX and factor IX assay performance. Results from the College of American Pathologists Survey Program. Arch Pathol Lab Med1990;114:135–41.Search in Google Scholar
45. Burns ER, Goldberg SN, Wenz B. Paradoxic effect of multiple mild coagulation factor deficiencies on the prothrombin time and activated partial thromboplastin time. Am J Clin Pathol1993;100:94–8.10.1093/ajcp/100.2.94Search in Google Scholar PubMed
46. Lawrie AS, Kitchen S, Purdy G, Mackie IJ, Preston FE, Machin SJ. Assessment of Actin FS and Actin FSL sensitivity to specific clotting factor deficiencies. Clin Lab Haematol1998;20:179–86.10.1046/j.1365-2257.1998.00122.xSearch in Google Scholar PubMed
47. Ray MJ, Hawson GA. A comparison of two APTT reagents which use silica activators. Clin Lab Haematol1989;11:221–32.10.1111/j.1365-2257.1989.tb00212.xSearch in Google Scholar PubMed
48. Lippi G, Mengoni A, Manzato F. Sensitivity of two commercial reagents for prothrombin time and activated partial thromboplastin time to isolate coagulation factor deficiencies. Eur J Lab Med1999;7:61–5.Search in Google Scholar
49. Shetty S, Ghosh K, Mohanty D. Comparison of four commercially available activated partial thromboplastin time reagents using a semi-automated coagulometer. Blood Coagul Fibrinolysis2003;14:493–7.10.1097/00001721-200307000-00011Search in Google Scholar PubMed
50. Fressinaud E, Veyradier A, Truchaud F, Martin I, Boyer-Neumann C, Trossaert M, et al. Screening for von Willebrand disease with a new analyzer using high shear stress: a study of 60 cases. Blood1998;91:1325–31.10.1182/blood.V91.4.1325Search in Google Scholar
51. Franchini M, Gandini G, Manzato F, Lippi G. Evaluation of the PFA-100® system for monitoring desmopressin therapy in patients with type 1 von Willebrand's disease. Haematologica2002;87:670.Search in Google Scholar
52. Franchini M. The platelet function analyzer (PFA-100): an update on its clinical use. Clin Lab2005;51:367–72.Search in Google Scholar
53. Hayward CPM, Harrison P, Cattaneo M, Ortel TL, Rao AK. Platelet function analyzer (PFA)-100 closure time in the evaluation of platelet disorders and platelet function. J Thromb Haemost2006;4:312–9.10.1111/j.1538-7836.2006.01771.xSearch in Google Scholar PubMed
54. Chee YL, Greaves M. Role of coagulation testing in predicting bleeding risk. Hematol J2003;4:373–8.10.1038/sj.thj.6200306Search in Google Scholar PubMed
55. Lippi G, Franchini M, Brocco G, Manzato F. Influence of the ABO blood type on the platelet function analyzer PFA-100. Thromb Haemost2001;85:369–70.10.1055/s-0037-1615707Search in Google Scholar
56. Sie P, Steib A. Central laboratory and point of care assessment of perioperative hemostasis. Can J Anaesth2006;53:S12–20.10.1007/BF03022248Search in Google Scholar PubMed
57. Hemker HC, Beguin S. Phenotyping the clotting system. Thromb Haemost2000;84:741–51.10.1055/s-0037-1614109Search in Google Scholar
58. Bosiger J. A systematic approach to the bleeding patient. Schweiz Rundsch Med Prax2004;93:1693–9.Search in Google Scholar
59. Gerotziafas GT, Depasse F, Busson J, Leflem L, Elalamy I, Samama MM. Towards a standardization of thrombin generation assessment: the influence of tissue factor, platelets and phospholipids concentration on the normal values of Thrombogram-Thrombinoscope assay. Thromb J2005;3:16.10.1186/1477-9560-3-16Search in Google Scholar PubMed PubMed Central
60. Hemker HC, Al Dieri R, Beguin S. Thrombin generation assays: accruing clinical relevance. Curr Opin Hematol2004;11:170–5.10.1097/01.moh.0000130314.33410.d7Search in Google Scholar PubMed
61. Luddington RJ. Thrombelastography/thromboelastometry. Clin Lab Haematol2005;27:81–90.10.1111/j.1365-2257.2005.00681.xSearch in Google Scholar PubMed
62. Kang Y, Marquez D, Lewis J, Bontempo F, Shaw B, Starzl T, et al. Intraoperative changes in blood coagulation and thrombelastographic monitoring in liver transplantation. Anesth Analg1985;64:888–96.10.1213/00000539-198509000-00008Search in Google Scholar
63. Shore-Lesserson L, Manspeizer H, DePerio M, Francis S, Vela-Cantos F, Ergin M. Thromboelastography-guided transfusion algorithm reduces transfusions in complex cardiac surgery. Anesth Analg1999;88:312–9.10.1213/00000539-199902000-00016Search in Google Scholar
64. Sorensen B, Ingerslev J. Tailoring haemostatic treatment to patient requirements-an update on monitoring haemostatic response using thrombelastography. Haemophilia2005;11(Suppl 1):1–6.10.1111/j.1365-2516.2005.01156.xSearch in Google Scholar PubMed
65. Ramsay M, Randall H, Burton E. Intravascular thrombosis and thromboembolism during liver transplantation: antifibrinolytic therapy indicated? Liver Transpl2004;10:310–4.10.1002/lt.20064Search in Google Scholar PubMed
66. Salooja N, Perry DJ. Thrombelastography. Blood Coagul Fibrinolysis2001;12:327–37.10.1097/00001721-200107000-00001Search in Google Scholar PubMed
67. Hemker HC, Beguin S. Thrombin generation: old wine into new wineskins. Thromb Haemost2003;90:764–5.10.1055/s-0037-1613492Search in Google Scholar
68. Hemker HC, Giesen P, Aldieri R, Regnault V, de Smed E, Wagenvoord R, et al. The calibrated automated thrombogram (CAT): a universal routine test for hyper- and hypocoagulability. Pathophysiol Haemost Thromb2002;32:249–53.10.1159/000073575Search in Google Scholar PubMed
69. Hemker HC, Wielders S, Kessels H, Beguin S. Continuous registration of thrombin generation in plasma, its use for the determination of the thrombin potential. Thromb Haemost1993;70:617–24.10.1055/s-0038-1649638Search in Google Scholar
70. Kumar R, Beguin S, Hemker HC. The effect of fibrin clots and clot-bound thrombin on the development of platelet procoagulant activity. Thromb Haemost1995;74:962–8.10.1055/s-0038-1649856Search in Google Scholar
71. Horne MK III, Cullinane AM, Merryman PK, Hoddeson EK. The effect of red blood cells on thrombin generation. Br J Haematol2006;133:403–8.10.1111/j.1365-2141.2006.06047.xSearch in Google Scholar PubMed
72. Carr ME Jr, Martin EJ. Evolving techniques for monitoring clotting in plasma and whole blood samples. Clin Lab2004;50:539–49.Search in Google Scholar
73. Siegemund T, Petros S, Siegemund A, Scholz U, Engelmann L. Thrombin generation in severe haemophilia A and B: the endogenous thrombin potential in platelet-rich plasma. Thromb Haemost2003;90:781–6.10.1160/TH03-01-0027Search in Google Scholar PubMed
74. Beltran-Miranda CP, Khan A, Jaloma-Cruz AR, Laffan MA. Thrombin generation and phenotypic correlation in haemophilia A. Haemophilia2005;11:326–34.10.1111/j.1365-2516.2005.01107.xSearch in Google Scholar PubMed
75. Varadi K, Negrier C, Berntorp E, Astermark J, Bordet JC, Morfini M, et al. Monitoring the bioavailability of FEIBA with a thrombin generation assay. J Thromb Haemost2003;1:2374–80.10.1046/j.1538-7836.2003.00450.xSearch in Google Scholar PubMed
76. McIntosh JH, Owens D, Lee CA, Raut S, Barrowcliffe TW. A modified thrombin generation test for the measurement of factor VIII concentrates. J Thromb Haemost2003;1:1005–11.10.1046/j.1538-7836.2003.00209.xSearch in Google Scholar PubMed
77. Allen GA, Wolberg AS, Oliver JA, Hoffman M, Roberts HR, Monroe DM. Impact of procoagulant concentration on rate, peak and total thrombin generation in a model system. J Thromb Haemost2004;2:402–13.10.1111/j.1538-7933.2003.00617.xSearch in Google Scholar PubMed
78. Shima M, Matsumoto T, Fukuda K, Kubota Y, Tanaka I, Nishiya K, et al. The utility of activated partial thromboplastin time (aPTT) clot waveform analysis in the investigation of hemophilia A patients with very low levels of factor VIII activity (FVIII:C) Thromb Haemost2002;87:436–41.10.1055/s-0037-1613023Search in Google Scholar
79. Beguin S, Keularts I, Al Dieri R, Bellucci S, Caen J, Hemker HC. Fibrin polymerization is crucial for thrombin generation in platelet-rich plasma in a VWF-GPIb-dependent process, defective in Bernard-Soulier syndrome. J Thromb Haemost2004;2:170–6.10.1111/j.1538-7836.2004.00558.xSearch in Google Scholar PubMed
80. Hedner U. Mechanism of action of factor VIIa in the treatment of coagulopathies. Semin Thromb Hemost2006;32(Suppl 1):77–85.10.1055/s-2006-939557Search in Google Scholar PubMed
81. Wegert W, Harder S, Bassus S, Kirchmaier CM. Platelet-dependent thrombin generation assay for monitoring the efficacy of recombinant Factor VIIa. Platelets2005;16:45–50.10.1080/09537100400008059Search in Google Scholar PubMed
82. Livnat T, Zivelin A, Martinowitz U, Salomon O, Seligsohn U. Prerequisites for recombinant factor VIIa-induced thrombin generation in plasmas deficient in factors VIII, IX or XI. J Thromb Haemost2006;4:192–200.10.1111/j.1538-7836.2005.01683.xSearch in Google Scholar PubMed
83. Sorensen B, Ingerslev J. Whole blood clot formation phenotypes in hemophilia A and rare coagulation disorders. Patterns of response to recombinant factor VIIa. Thromb Haemost2004;2:102–10.10.1111/j.1538-7836.2004.00528.xSearch in Google Scholar PubMed
84. Lippi G, Salvagno GL, Montagnana M, Guidi GC. Reliability of the thrombin generation assay on frozen-thawed platelet rich plasma. Clin Chem2006;52:1827–8.10.1373/clinchem.2006.070086Search in Google Scholar PubMed
85. Lippi G, Franchini M, Montagnana M, Salvagno GL, Poli G, Guidi GC. Quality and reliability of routine coagulation testing. Can we trust that sample? Blood Coagul Fibrinolysis2006;17:513–9.10.1097/01.mbc.0000245290.57021.46Search in Google Scholar PubMed
86. Matsumoto T, Shima M, Takeyama M, Yoshida K, Tanaka I, Sakurai Y, et al. The measurement of low levels of factor VIII or factor IX in hemophilia A and hemophilia B plasma by clot waveform analysis and thrombin generation assay. J Thromb Haemost2006;4:377–84.10.1111/j.1538-7836.2006.01730.xSearch in Google Scholar PubMed
87. Kasuda S, Tanaka I, Shima M, Matsumoto T, Sakurai Y, Nishiya K, et al. Effectiveness of factor VIII infusions in haemophilia A patients with high responding inhibitors. Haemophilia2004;10:341–6.10.1111/j.1365-2516.2004.00907.xSearch in Google Scholar PubMed
88. Sahud MA. Factor VIII inhibitors. Laboratory diagnosis of inhibitors. Semin Thromb Hemost2000;26:195–203.10.1055/s-2000-9823Search in Google Scholar PubMed
89. Ramjee MK. The use of fluorogenic substrates to monitor thrombin generation for the analysis of plasma and whole blood coagulation. Anal Biochem2000;277:11–8.10.1006/abio.1999.4380Search in Google Scholar PubMed
90. Altman R, Scazziota AS, de Lourdes Herrera M, Gonzalez C. Thrombin generation by activated factor VII on platelet activated by different agonists. Extending the cell-based model of hemostasis. Thromb J2006;4:5.10.1111/j.1538-7836.2006.02088.xSearch in Google Scholar PubMed
91. Hedner U. Mechanism of action, development and clinical experience of recombinant FVIIa. J Biotechnol2006;124:747–57.10.1016/j.jbiotec.2006.03.042Search in Google Scholar PubMed
92. Ludlam CA, Powderly WG, Bozzette S, Diamond M, Koerper MA, Kulkarni R, et al. Clinical perspectives of emerging pathogens in bleeding disorders. Lancet2006;367:252–61.10.1016/S0140-6736(06)68036-7Search in Google Scholar
93. Farrugia A, Robert P. Plasma protein therapies: current and future perspectives. Best Pract Res Clin Haematol2006;19:243–58.10.1016/j.beha.2005.01.002Search in Google Scholar PubMed
94. Marchant RE, Kang I, Sit PS, Zhou Y, Todd BA, Eppell SJ, Lee I. Molecular views and measurements of hemostatic processes using atomic force microscopy. Curr Protein Pept Sci2002;3:249–74.10.2174/1389203023380611Search in Google Scholar PubMed
95. Santos NC, Castanho MA. An overview of the biophysical applications of atomic force microscopy. Biophys Chem2004;107:133–49.10.1016/j.bpc.2003.09.001Search in Google Scholar PubMed
96. Laposata ME, Laposata M, Van Cott EM, Buchner DS, Kashalo MS, Dighe AS. Physician survey of a laboratory medicine interpretive service and evaluation of the influence of interpretations on laboratory test ordering. Arch Pathol Lab Med2004;128:1424–7.10.5858/2004-128-1424-PSOALMSearch in Google Scholar PubMed
©2007 by Walter de Gruyter Berlin New York
